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EXCEL decision analytic model we considered disease incidence and sequelae, sero-
type coverage and health care utilization to compare costs and impact of PCV13 vs. 
PCV10, vs. PCV7 and vs. no vaccination on invasive pneumococcal disease (IPD), 
pneumonia, and otitis media, among vaccinated children (direct effects only) and the 
entire population while including indirect (herd) effects. Epidemiological data from 
Greek published studies and the National Statistical Service were supplemented by 
expert panel opinion and international literature. Published costs from the Athens 
University Paediatric Hospital and government price bulletins were employed, assum-
ing price parity between PCV7 and PCV13. Only hospital treatment costs were con-
sidered and outcomes were discounted at 3%.     RESULTS: Immunization with PCV7, 
PCV10, and PCV13 would eliminate 74%, 82%, and 89% of IPD among vaccinated 
children, respectively. Assuming 84% vaccination rate with the recommended 31 
dose schedule and adding indirect beneﬁts, PCV13v vaccination would reduce IPD 
incidence by 63% in the total population versus no vaccination and would prevent 
an additional 6 and 4 deaths annually compared to PCV7/10 respectively. PCV13 
vaccination would annually save a158K or a189K versus PCV7 and PCV10 respec-
tively estimating only direct beneﬁts, and a803K or a2324K respectively including 
indirect effects. Compared to no vaccination annual cost savings reached a2403K 
(a903K if considering only direct beneﬁts). CONCLUSIONS: Introducing PCV13 in 
the Greek National Immunization schedule would provide additional protection 
against pneumococcal disease and cost savings for the health care system vs. existing 
PCV vaccines.
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OBJECTIVES: Persons with chronic hepatitis B virus infection (HBV) are at risk of 
developing cirrhosis and hepatocellular carcinoma. Early detection of chronic HBV 
infection through screening and treatment of eligible patients has the potential to 
contribute to secondary prevention of HBV. We assessed the costs-effectiveness of 
systematic screening for chronic hepatitis B (CHB) of ﬁrst generation migrants in The 
Netherlands from intermediate and high endemic countries. METHODS: Epidemio-
logical data of expected numbers of patients with active CHB in the target population 
and data on the costs of a screening program were combined with the outcomes of a 
Markov model in terms of costs and QALYs for patients with and without treatment, 
using a life time horizon. The base-case assumptions were an HBV prevalence of 
3.35%, 35% participation in screening, specialist consultation for 58% of patients 
selected for referral, and 75% of eligible patients starting treatment. RESULTS: 
Compared to the status quo, a one-time screening can reduce mortality of liver related 
diseases by 10%, from 1073 to 965 deaths. Using base case estimates, the incremental 
cost effectiveness ratio (ICER) of screening compared to the status quo is a8966 per 
QALY gained. The ICER varied between a7,936 and a11,705 per QALY gained in 
univariate sensitivity analysis, varying parameter values of HBV prevalence, participa-
tion rate, successful referral and treatment compliance. In multivariate sensitivity 
analysis for treatment effectiveness the ICER varied between a7,222 and a15,694, and 
for disease progression in natural history from a5,568 to a60,418. CONCLUSIONS: 
Early detection and treatment of eligible patients has a large impact on liver related 
health outcomes. A systematic screening program for chronic HBV infection targeted 
at ﬁrst generation migrants is likely to be cost effective, even at low estimates for the 
HBsAg prevalence, participation, referral and treatment compliance.
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OBJECTIVES: To determine the cost effectiveness of Pegatron combination therapy 
compared with no treatment for Australian patients who have failed an initial attempt 
at interferon-based (pegylated or non-pegylated) therapy. METHODS: The structure 
of the Markov model, utility values and transition probabilities were based on the 
literature. SVR and virologic response rates by genotype and ﬁbrosis were obtained 
from EPIC3 (Evaluation of PegIntron in Control of Hepatitis C Cirrhosis). EPIC3 is 
a large, prospective, multiphase clinical program evaluating the retreatment of chronic 
Hepatitis C patients with signiﬁcant ﬁbrosis/cirrhosis in whom previous treatment 
with nonpegylated or PEG-IFN alfa plus ribavirin was ineffective (ie, patients experi-
enced virologic nonresponse or relapse). Resource utilization was determined by a 
modiﬁed Delphi approach for various CHC health states. The population parameters 
used in the model reﬂect the mix of moderate and cirrhotic patients infected with dif-
ferent HCV genotypes, local medical management protocols, liver transplantation 
rates, and age-speciﬁc mortality rates of CHC patients in Australia. RESULTS: In the 
trial (N  1336), SVR was achieved by 22.6% (99% CI 19.7–25.6) of subjects. Of 
the 499 subjects with undetectable HCV-RNA viral load after 12 weeks of treatment, 
56.5% (95% CI 52.2–60.9) achieved an SVR. After discounting of costs and outcomes 
and extending to a life-time model, the modelled ICER was $12,887 Australian dollars 
per QALY gained. Sensitivity analyses indicated that when parameters are varied 
across reasonable ranges of their base case values, the ICER ratios range from cost 
saving to less than $50,000 per QALY gained. CONCLUSIONS: Based on clinical 
evidence, Pegatron treatment for patients who have failed prior interferon alfa com-
bination therapy is highly cost-effective relative to no treatment. Thus, allowing one 
course of retreatment for individuals who have failed an initial attempt at interferon 
alfa-based therapy is a cost effective approach to preventing further extension of the 
Hepatitis C epidemic in Australia.
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OBJECTIVES: To assess the cost-effectiveness of palivizumab as a preventive treat-
ment against respiratory syncytial virus (RSV) infection in children with congenital 
heart disease (CHD) in Korea. METHODS: A decision analytic model was developed 
to determine cost-effectiveness of prophylaxis with 5 monthly doses of palivizumab 
injection as compared to no prophylaxis. The analysis was based on a lifetime follow-
up period to capture the impact of palivizumab on long-term morbidity and mortality 
resulting from RSV infection. Efﬁcacy of prophylaxis was measured as the number of 
RSV hospitalizations and mortality avoided, and derived from literature. Prophylaxis 
cost was deﬁned as a sum of drug acquisition costs and costs associated with outpa-
tient visits occurred to receive palivizumab injection. Average cost for a hospitalization 
with RSV was calculated on the basis of 40 conﬁrmed cases of RSV hospitalization 
occurred between 2006 and 2008 from the two hospitals participated in this study. 
Future costs and effectiveness were discounted at 5%. RESULTS: In children with 
CHD, prophylaxis with palivizumab compared with no prophylaxis had an incremen-
tal cost-effectiveness ratio of 12.0 million Korean won (KW, 1 US dollar is approxi-
mately equal to 1000 KW) per life year gained (LYG) and 6.9 million KW per LYG 
from payer’s and societal perspective, respectively. One-way sensitivity analyses and 
scenario analysis conﬁrmed the robustness of the model. CONCLUSIONS: The esti-
mated ICER of palivizumab is within the generally accepted willingness-to-pay thresh-
old of ICER in Korean society. Thus, the use of palivizumab is considered cost-effective 
in children with CHD in Korea.
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OBJECTIVES: Varicella (chickenpox) affects most people and imposes an important 
burden on health care systems. It is, however, a preventable disease with childhood 
mass vaccination. The cost-effectiveness in France of replacing routine MMR with 
MMRV (Measles, Mumps, Rubella and Varicella) vaccine was explored. METHODS: 
The epidemiology of varicella and consequences of implementing different vaccination 
programs were investigated using an age-structured dynamic model. The basecase 
assumed one dose protects for 17 years and two doses for three times longer and no 
natural immunity boosting. MMRV vaccination was assumed to replace up to 80% 
of MMR over 5 years. An alternative scenario was analysed to assess the impact of 
an improved MMRV vaccination coverage (replacement of 100% of MMR over a 2-
year period plus a catch up program for eight years in 5-year olds). A MMRV vaccine 
price of a54 per dose was assumed. RESULTS: In the basecase, varicella incidence 
decreased from 12,707 per million person-years before vaccination to 4,746 after 30 
years of vaccination (steady state). With fewer varicella cases and associated complica-
tions, annual outpatient and hospital costs decrease by 32%. The cost per quality-
adjusted life year (QALY) gained after 30 years was a3347 (95%CI 1; 9927). With 
the scenario of improved vaccination coverage, varicella incidence decreased to 2,085 
per million person-years and the cost per QALY was estimated at a3284 (95%CI 15; 
8916) after 30 years of vaccination. If a societal perspective is considered (including 
lost productivity costs), both the basecase and alternative vaccination scenario pro-
duced more QALYs and cost-savings. CONCLUSIONS: Gradual and partial replace-
ment of MMR with MMRV vaccination is predicted to dramatically decrease varicella 
incidence, and, to be highly cost-effective from a payer perspective and cost-saving 
from a societal perspective. A more intensive MMRV coverage is predicted to further 
reduce varicella incidence while remaining a highly cost-effective vaccination 
strategy.
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OBJECTIVES: To Demonstrate that doripenem is a cost-effective option compared 
with the most utilized treatments in patients with Ventilator-Associated Pneumonia 
(VAP) in Mexico, from the point of view of the Mexican Institute of Social Security 
(IMSS). METHODS: A decision tree was elaborated for patients with VAP. Patients 
were assumed to be treated with doripenem, imipenem or piperacilin-tazobactam (PT) 
